Rebecca Taub, M.D.

Rebecca Taub, M.D.

Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical OfficeratMadrigal Pharmaceuticals· In proxies 2021–2025

Pay in FY2025+15% from the year before · Madrigal Pharmaceuticals stock +88.7% the same year

Rebecca Taub, M.D. was paid $6.9M in FY2025 (Dec), up 15%. Madrigal Pharmaceuticals stock rose 88.7% that year.

Pay$100 in the stock at the end of FY20 → $524
Pay is from the Summary Compensation Table of each Madrigal Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Madrigal PharmaceuticalsPublic company · 5 yr
    • Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer2021 – Present · 5 yrStock in role +259%
  2. BriaCell Therapeutics Corp.Public company · 7 yr
    • Director2019 – Present · 7 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Madrigal PharmaceuticalsDirector · 9 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?